drugset / Trial / NCT00106379

Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients

NCT00106379

Phase 4 Completed 52 enrolled Gilead Sciences
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to provide long-term clinical safety and efficacy data for tenofovir disoproxil fumarate and emtricitabine in HIV-infected patients experiencing various degrees of renal impairment.

Timeline

Start
2004-10
Primary completion
Completion
2007-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenofovir disoproxil fumarate Small molecule 300 mg
Subject emtricitabine Other / unclassified 200 mg